Is there a metabolic rationale to support a weight loss programme to prevent diabetes?

British Journal of Diabetes and Vascular Disease

Volumn 3, Issue SUPPL. 1, 2003, Pages

  Lean, Mike ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Appetite; Diabetes prevention; Diet; Exercise; Obesity; Type 2 diabetes

Indexed keywords

ANTIOBESITY AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CONTRACEPTIVE AGENT; CORTICOSTEROID; CYPROHEPTADINE; INSULIN; LITHIUM; MEGLITINIDE; METFORMIN; PIZOTIFEN; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN; THIAZOLIDINE DERIVATIVE; VALPROIC ACID;

ADIPOSE TISSUE; APPETITE; ARTICLE; BODY FAT; BODY MASS; BODY WEIGHT DISORDER; CLINICAL TRIAL; COST CONTROL; COST OF ILLNESS; DIABETIC DIET; EXERCISE; HEALTH PROGRAM; HORMONAL REGULATION; HORMONE RELEASE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROGNOSIS; STOMACH SURGERY; WEIGHT REDUCTION;

EID: 0038574730     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/1474651403003001s0401     Document Type: Article

References (33)

1. Pi-Sunyer FX. Weight and non-insulin-dependent diabetes mellitus. Am J Clin Nutr 1996;63(suppl 3):426S-429S.
2. Fuchtenbusch M, Standl E, Schatz H. Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2000;108:151-63.
3. United Kingdom Prospective Diabetes Study (UKPDS) 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995;310:83-8.
4. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995; 122:481-6.
5. Lindahl B, Weinehall L, Asplund K, Hallmans G. Screening for impaired glucose tolerance. Results from a population-based study in 21,057 individuals. Diabetes Care 1999;22:1988-92.
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
7. American Diabetes Association. Nutrition recommendations and principles for people with diabetes mellitus (Position Statement). Diabetes Care 2001;24:S44-S47.
8. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabetic Medicine 1999;16:716-30.
9. Lean ME. Obesity - what are the current treatment options? Exp Clin Endocrinol Diabetes 1998;106(suppl 2):S22-S26.
10. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992;16:397-415.
11. Lean MEJ, Powrie JK, Anderson AS, Garthwaite PH. Obesity, weight loss and prognosis in type 2 diabetes. Diabetic Med 1990;7:228-33.
12. Williamson DF, Pamuk E, Thun M, Flanders D, Byers T, Heath C. Prospective study of intentional weight loss and mortality in overweight white men aged 40-64 years. Am J Epidemiol 1999;149:491-503.
13. Ravussin E, Swinburn A. Insulin resistance is a result, not a cause of obesity. Socratic debate: the pro side. Progress in Obesity Research. Eds: A Angel, H Anderson, C Bouchard, L Leiter and R Mendelson, Chapter 23 173-8 (1996).
14. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
15. Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
16. Sjöström CD, Peltonen M, Wedel H, Sjostrom L. Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension 2000;36:20-5.
17. Mora S, Pessin JE. An adipocentric view of signaling and intracellular trafficking. Diabetes Metab Res Rev 2002;18:345-56.
18. Halle M, Berg A, Northoff H, Keul J. Importance of TNF-alpha and leptin in obesity and insulin resistance: a hypothesis on the impact of physical exercise. Exerc Immunol Rev 1998;4:77-94.
19. Lahlou N, Clement K, Carel JC et al. Soluble leptin receptor in serum of subjects with complete resistance to leptin: relation to fat mass. Diabetes 2000;49:1347-52.
20. Tsofliou F, Pitsiladis Y, Malkova D, Wallace M, Lean MEJ. Moderate physical activity permits acute coupling between leptin and appetite-satiety measures in obese women. IJO 2003 (in press).
21. Jequier E. Leptin signaling, adiposity, and energy balance. Ann N Y Acad Sci 2002;967:379-88.
22. Chu NF, Stampfer MJ, Spiegelman D et al. Dietary and lifestyle factors in relation to plasma leptin concentrations among normal weight and overweight men. Int J Obes Relat Metab Disord 2001;25:106-14.
23. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994;43:1271-8.
24. Bullo-Bonet M, Garcia-Lorda P, Lopez-Soriano FJ et al. Tumour necrosis factor, a key role in obesity? FEBS Lett 1999;451:215-19.
25. Way JM, Gorgun CZ, Tong Q et al. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 2001;276:25651-3.
26. Hegele RA, Kraw ME, Ban MR et al. Elevated Serum C-Reactive Protein and Free Fatty Acids Among Nondiabetic Carriers of Missense Mutations in the Gene Encoding Lamin A/C (LMNA) With Partial Lipodystrophy. Arterioscler Thromb Vasc Biol 2003;23:111-16.
27. Adamczak M, Wiecedilicek A, Funahashi T et al. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 2003;16:72-5.
28. Ukkola O, Santaniemi M. Adiponectin: a link between excess adiposity and associated comorbidities? J Mol Med 2002;80:696-702.
29. Lean MEJ, Powrie JK, Anderson AS, Garthwaite PH. Obesity, weight loss and prognosis in type 2 diabetes. Diabetic Medicine 1990;7:228-33.
30. Astrup A, Buemann B, Flint A, Raben A. Low-fat diets and energy balance: how does the evidence stand in 2002? Proc Nutr Soc 2002; 61:299-309.
31. Kornegay CJ, Vasilakis-Scaramozza C, Jick H. Incident diabetes associated with antipsychotic use in the United Kingdom general practice research database. J Clin Psychiatry 2002;63:758-62.
32. Lindenmayer JP, Nathan AM, Smith RC. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry 2001;62(suppl 23):30-8.
33. Lean MEJ, Pajonk FG. Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes. Diabetes Care 2003 (in press).